MCT1 activity defines an aggressive metabolic phenotype and therapeutic target in non-small cell lung cancer
Cameron, R. B.; Shema, K. E.; Dubois, N.; Clare, M. G.; Hammond, N. G.; Kaur, M.; Chang, B. K.; Schechter, E. G.; Hsiang, J.; Marczenia, Z.; Garassino, M. C.; Cai, L.; Bestvina, C. M.; Mathews, T. P.; Tasdogan, A.; Shah, H.; Faubert, B.
Show abstract
Lactate uptake through monocarboxylate transporter 1 (MCT1) is associated with aggressive disease in non-small cell lung cancer (NSCLC), but how lactate transport supports tumor metabolism remains incompletely understood. Integrating stable isotope tracing, metabolomics, and transcriptomics across patient tumors, animal models, and cultured cells, we show that elevated lactate utilization and SLC16A1 expression correlate with worse clinical outcomes in NSCLC. Although MCT1 inhibition with AZD3965 does not significantly impair tumor growth as a monotherapy, it depletes purine-associated metabolite pools, alters redox balance, and induces a conserved transcriptional response involving MYC target dysregulation and suppression of nucleotide metabolism genes. Addition of exogenous hypoxanthine, or expression of the E. coli-derived NADH-producing enzyme soluble transhydrogenase, partially rescues the effects of MCT1 inhibition. Importantly, this metabolically compromised state sensitizes NSCLC to nucleotide-targeting chemotherapies, including pemetrexed. These findings reveal that MCT1 mediated lactate uptake sustains nucleotide homeostasis in NSCLC, and that its inhibition exposes a context-dependent vulnerability that can be leveraged to enhance chemotherapy efficacy.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Imaging the master regulator of the antioxidant response in non-small cell lung cancer with positron emission tomography 95%
- Mitochondria preserve an autarkic one-carbon cycle to confer growth-independent cancer cell migration and metastasis 93%
- Multimodal imaging reveals a lysosomal drug reservoir that drives heterogeneous distribution of PARP inhibitors 93%
Similar papers in this journal
- Mitochondrial-encoded complex I impairment induces a targetable dependency on aerobic fermentation in Hürthle cell carcinoma of the thyroid 94%
- Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma 92%
- Paradoxical activation of oncogenic signaling as a cancer treatment strategy 92%
Similar papers in this journal
- Alanine Catabolism as a Targetable Vulnerability for MYC-Driven Liver Cancer 94%
- Branched-Chain Amino Acid Metabolic Reprogramming Orchestrates Drug Resistance to EGFR Tyrosine Kinase Inhibitors 94%
- Androgen receptor inhibition induces metabolic reprogramming and increased reliance on oxidative mitochondrial metabolism in prostate cancer 92%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.